Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Som
Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan. For further discussion visit www.HemOnc101.com. Treatment of stem cell transplantation candidate patient with multiple myeloma Multiple myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin antibody. This clone of plasma cells proliferates in the bone marrow and often results in extensive skeletal destruction with osteolytic lesions, and pathologic fractures. The diagnosis of multiple myeloma is often suspected because of one (or more) of the following clinical presentations. 1-Bone pain with lytic lesions discovered on routine skeletal films. 2-An increased total serum protein concentration and/or the presence of a monoclonal protein in the urine or serum. 3-High Calcium levels (Hypercalcemia), which is either symptomatic or discovered incidentally. 4-Acute kidney failure or worsening kidney function. It is also important to evaluate patients suspected of having MM in a timely fashion since a major delay in diagnosis has been associated with a negative impact on the disease course. There have many been recent treatments that have made a substantial impact in the treatment of multiple myeloma in the last several years. Here, Dr. Tony Talebi discusses the treatment of stem cell transplantation candidate patient with multiple myeloma with Dr. Judy Ratzan, associate professor of medicine at the University of Miami Sylvester … Video Rating: 0 / 5
A guide to the practice of stem cell transplantation, its status in the treatment of various disorders and the problems that arise after transplantation, aimed at the whole transplant team.An up to date guide to best practice in the use of stem cell transplantation, covering current status in the treatment of malignant and non-malignant conditions, practical aspects and problems such as infection and graft versus host disease.Has a practical, accessible approach with free use of algorithms, list
Dr. Henry Fung, Director of the Section of Stem Cell Transplantation at Rush University Medical Center joins Chicago Blood Cancer Foundation founders Charlene McMann and Scott Seaman to discuss stem cell transplants. Dr. Fung addresses the procedure, the benefits and risks, developments, uses for blood cancers and other conditions, and the future of stem cell transplantation. This is part 1 of 2 of the episode of Chicago Blood Cancer Foundation’s “Battling and Beating Cancer” TV Show. Video Rating: 5 / 5
2008 Rare Neuroimmunologic Disorders Symposium Hematopoietic Stem Cell Transplantation in Multiple Sclerosis James Bowen, MD Transverse Myelitis Association Video Rating: 5 / 5
(out of reviews)
